John R. Eckardt

3.8k citations

85 papers · 3.2k indexed · h-index 31

Oncology top 1%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 5%
Epidemiology top 5%
Genetics top 5%

Co-authors: Howard A. Burris Daniel D. Von Hoff Geoffrey R. Weiss John G. Kuhn Susan G. Hilsenbeck G I Rodriguez Mace L. Rothenberg Lon Smith
Topics: Cancer therapeutics and mechanisms (42 papers)Lung Cancer Research Studies (42 papers)Neuroendocrine Tumor Research Advances (20 papers)
Cited by: Oncology Genetics Molecular Biology
Journals: Journal of Clinical Oncology Blood JNCI Journal of the National Cancer Institute
Partner nations: United States France United Kingdom

In The Last Decade

John R. Eckardt

83 papers receiving 3.0k citations

Peers

Countries citing papers authored by John R. Eckardt

Since Specialization

Citations

This map shows the geographic impact of John R. Eckardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Eckardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Eckardt more than expected).

Fields of papers citing papers by John R. Eckardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Eckardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Eckardt. The network helps show where John R. Eckardt may publish in the future.

Co-authorship network of co-authors of John R. Eckardt

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Eckardt. A scholar is included among the top collaborators of John R. Eckardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Eckardt. John R. Eckardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) 2011 ·Annals of Hematology ·Amanda F. Cashen,Mark Juckett,(unknown),Mark R. Litzow,Patrick J. Flynn,John R. Eckardt,Betsy LaPlant,Kristina Laumann,Charles Erlichman,John F. DiPersio	53
2	A Phase I Study of 7- t -Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies 2010 ·Clinical Cancer Research ·Susanne M. Arnold,John J. Rinehart,Eleftheria Tsakalozou,John R. Eckardt,Scott Z. Fields,Brent J. Shelton,Philip A. DeSimone,Bryan K. Kee,Jeffrey A. Moscow,Markos Leggas	23
3	Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Silvia Novello,Francisco Pimentel,Jean‐Yves Douillard,Mary O’Brien,Joachim von Pawel,John R. Eckardt,Astra M. Liepa,Lorinda Simms,Carla Visseren‐Grul,Luis Paz‐Ares	10
4	Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer 2007 ·Journal of Clinical Oncology ·John R. Eckardt,Joachim von Pawel,Jean-Louis Pujol,Zsolt Pápai,Élisabeth Quoix,Andrea Ardizzoni,(unknown),A. Preston,G. Dane,Graham Ross	274
5	Development of docetaxel inadvanced non-small-cell lung cancer 2004 ·Lung Cancer ·Chandra P. Belani,John R. Eckardt	19
6	Options for first- and second-line therapy in small cell lung cancer — a workshop discussion 2003 ·Lung Cancer ·Nick Thatcher,John R. Eckardt,Mark A. Green	13
7	Challenging the platinum combinations in the chemotherapy of NSCLC 2002 ·Lung Cancer ·Jean‐Yves Douillard,John R. Eckardt,Giorgio V. Scagliotti	23
8	Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors 1999 ·Journal of Clinical Oncology ·S. Gail Eckhardt,Jinee Rizzo,Kevin Sweeney,G. Cropp,Sharyn D. Baker,Maura A. Kraynak,John G. Kuhn,Miguel A. Villalona‐Calero,Lisa A. Hammond,Geoffrey R. Weiss,(unknown),Lon Smith,Ronald Drengler,John R. Eckardt,(unknown),Alison L. Hannah,Daniel D. Von Hoff,Eric K. Rowinsky	55
9	A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion 1998 ·Investigational New Drugs ·Gladys Rodriguez,John G. Kuhn,Geoffrey R. Weiss,(unknown),Pamela New,Suzanne M. Fields,John R. Eckardt,Liz Campbell,Gary M. Clark,Susan G. Hilsenbeck,Daniel D. Von Hoff	2
10	Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. 1997 ·Journal of Clinical Oncology ·G.J. Creemers,C J Gerrits,John R. Eckardt,Jan H.M. Schellens,Howard A. Burris,André Planting,G I Rodriguez,Walter J. Loos,I Hudson,Colin Broom,Jaap Verweij,Daniel D. Von Hoff	66
11	Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma 1997 ·Annals of Oncology ·Éric Raymond,Howard A. Burris,Eric K. Rowinsky,John R. Eckardt,G I Rodriguez,Lee Smith,Geoffrey R. Weiss,Daniel D. Von Hoff	31
12	Antitumor activity of docetaxel 1997 ·American Journal of Health-System Pharmacy ·John R. Eckardt	18
13	A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer 1996 ·Anti-Cancer Drugs ·Geoffrey R. Weiss,(unknown),Carl deMoor,David Rinaldi,Gladys Rodriguez,John R. Eckardt,(unknown),Daniel D. Von Hoff	3
14	A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium 1996 ·Annals of Oncology ·S. Gail Eckhardt,Howard A. Burris,John R. Eckardt,Geoffrey R. Weiss,Gladys Rodriguez,(unknown),David Rinaldi,Robert A. Barrington,(unknown),Kazuko Masuo,K Sudo,Ryo Atsumi,Toshihiro Oguma,(unknown),Suzanne M. Fields,Leslie Smetzer,Daniel D. Von Hoff	34
15	A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors 1995 ·Cancer Chemotherapy and Pharmacology ·Geoffrey R. Weiss,John G. Kuhn,Jinee Rizzo,Lon Smith,Gladys Rodriguez,John R. Eckardt,Howard A. Burris,(unknown),(unknown),Daniel D. Von Hoff	12
16	Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. 1995 ·Journal of Clinical Oncology ·David Rinaldi,Howard A. Burris,F. Andrew Dorr,James R. Woodworth,John G. Kuhn,John R. Eckardt,Gladys Rodriguez,Silvia Corso,Suzanne M. Fields,Chris Langley	132
17	Activity of Intoplicine (RP60475), a New DNA Topoisomerase I and II Inhibitor, Against Human Tumor Colony-Forming Units In Vitro 1994 ·JNCI Journal of the National Cancer Institute ·John R. Eckardt,Howard A. Burris,(unknown),Marie-Christine Bissery,(unknown),Gary M. Clark,Daniel D. Von Hoff	10
18	Heat shock proteins and drug resistance 1994 ·Breast Cancer Research and Treatment ·Suzanne A.W. Fuqua,Steffi Oesterreich,Susan G. Hilsenbeck,Daniel D. Von Hoff,John R. Eckardt,C. Kent Osborne	98
19	Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion 1994 ·Anti-Cancer Drugs ·Howard A. Burris,Ahmad Awada,John G. Kuhn,John R. Eckardt,Patrick Cobb,(unknown),(unknown),Lon Smith,Daniel D. Von Hoff	40
20	Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. 1993 ·Journal of Clinical Oncology ·Howard A. Burris,(unknown),John G. Kuhn,(unknown),Lee Smith,Don W. Shaffer,Suzanne M. Fields,Geoffrey R. Weiss,John R. Eckardt,Gladys Rodriguez	120

About John R. Eckardt

John R. Eckardt is a scholar working on Oncology, Genetics and Molecular Biology, having authored 85 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (42 papers), Lung Cancer Research Studies (42 papers) and Neuroendocrine Tumor Research Advances (20 papers). The work is most often cited by research in Oncology (2.2k citations), Genetics (313 citations) and Molecular Biology (1.7k citations). John R. Eckardt has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Howard A. Burris, Daniel D. Von Hoff, Geoffrey R. Weiss, John G. Kuhn, Susan G. Hilsenbeck, G I Rodriguez, Mace L. Rothenberg, Lon Smith, David Rinaldi and S. Gail Eckhardt. Their work appears in journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact